Get the Stockscreener App
0.00
100.00%
-12.58
Astria Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
See More
Previous Close:
$12.58
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$718.13M
Revenue:
-
Net Income/Loss:
$-72.89M
P/E Ratio:
0.00
EPS:
-2.42
Net Cash Flow:
$-68.47M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$13.29
Astria Therapeutics Inc Stock (ATXS) Company Profile
Name
Astria Therapeutics Inc
Sector
Industry
Phone
617-349-1971
Address
22 BOSTON WHARF ROAD, BOSTON
Compare ATXS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
0.00 | 718.13M | 0 | -72.89M | -68.47M | -2.42 |
VRTX
Vertex Pharmaceuticals Inc
|
425.08 | 111.27B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
595.39 | 62.97B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
803.64 | 51.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.00 | 39.47B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
152.04 | 34.80B | 742.00K | -1.37B | -1.07B | -7.0731 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jul-29-24 | Initiated | TD Cowen | Buy |
| Mar-28-23 | Initiated | Evercore ISI | Outperform |
View All
Astria Therapeutics Inc Stock (ATXS) Latest News
Ikena Oncology stock (US4517401090): takeover by Astria Therapeutics reshapes the story - AD HOC NEWS
BioCryst Maintains 2026 ORLADEYO Revenue Guidance Amid Growth - HarianBasis.co
BioCryst (NASDAQ: BCRX) takes $697.8M navenibart R&D hit after Astria deal - Stock Titan
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
BioCryst To Acquire Astria Therapeutics In $700M Deal - MSN
Cantor Fitzgerald Downgrades Astria Therapeutics (ATXS) - MSN
HC Wainwright & Co. Downgrades Astria Therapeutics (ATXS) - MSN
Street Watch: Whats the MACD signal for Astria Therapeutics IncEntry Point & Reliable Price Breakout Alerts - baoquankhu1.vn
Whale Trades: Is Astria Therapeutics Inc trading at a discount2026 Year in Review & Verified Technical Signals - baoquankhu1.vn
Aug Momentum: Is Astria Therapeutics Inc stock forming a cup and handle2026 EndofYear Setup & Expert Curated Trade Setups - baoquankhu1.vn
Published on: 2026-04-08 03:02:22 - baoquankhu1.vn
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer - Yahoo Finance
How The BioCryst Pharmaceuticals (BCRX) Narrative Is Shifting With Astria Deal And FY26 Targets - Yahoo Finance
Meme Stocks: Can Astria Therapeutics Inc ride the EV wave2026 PostEarnings & Accurate Intraday Trade Tips - baoquankhu1.vn
Can Astria Therapeutics Inc reach all time highs this yearQuarterly Portfolio Review & Low Risk Entry Point Guides - baoquankhu1.vn
Astria Therapeutics (ATXS) price target decreased by 17.94% to 21.62 - MSN
Performance Recap: Should I invest in Astria Therapeutics Inc before earningsQuarterly Portfolio Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
Trend Report: Whats the fair value of Astria Therapeutics Inc stock2026 Big Picture & Real-Time Buy Signal Alerts - baoquankhu1.vn
BioCryst Pharmaceuticals Sees Profitable Quarter Amid Strategic Moves - StocksToTrade
BioCryst Stock Surges After Strong Q4 Earnings and Astria Acquisition - timothysykes.com
ATXS SEC FilingsAstria Therapeutics Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush - Yahoo Finance
Analyst Upgrade: Can Astria Therapeutics Inc stock outperform in a bear marketInsider Buying & AI Forecasted Stock Moves - baoquankhu1.vn
Risks Report: Whats the fair value of Astria Therapeutics Inc stockJuly 2025 Pullbacks & Verified Entry Point Signals - baoquankhu1.vn
Moving Averages: What hedge funds are buying Astria Therapeutics IncAnalyst Upgrade & Growth Focused Stock Pick Reports - baoquankhu1.vn
Evercore ISI sees long-term growth potential for BioCryst Pharmaceuticals, Inc. (BCRX) following Astria acquisition - MSN
Less bullish OX40 field as Kyowa bid plowed under - BioWorld News
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Net Income Turns Positive And Astria Deal Expands HAE Portfolio - Yahoo Finance
BioCryst’s First Profitable Year Recasts Hereditary Angioedema Growth Story - Yahoo Finance
Where is BioCryst Pharmaceuticals (BCRX) Headed According to the Street? - Finviz
BCRX: $400M Blackstone term loan funds Astria deal, secured by assets, matures 2031, SOFR+4.5% - TradingView
BioCryst (BCRX) Achieves Record Revenue and Profitability Milest - GuruFocus
BioCryst (NASDAQ: BCRX) posts 2025 profit, keeps 2026 revenue outlook - Stock Titan
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Rare-disease drugmaker BioCryst turns first annual profit, wins FDA OK for kids - Stock Titan
BioCryst (BCRX) Is Up 9.5% After Astria Deal And HAE Data Spotlight Has The Bull Case Changed? - Yahoo Finance
ATXS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aug Spikes: Can Astria Therapeutics Inc ride the EV waveQuarterly Earnings Report & Community Verified Trade Signals - baoquankhu1.vn
Evercore ISI Sees Long-Term Growth Potential For BioCryst Pharmaceuticals, Inc. (BCRX) Following Astria Acquisition - Insider Monkey
What are the future prospects of Astria Therapeutics Inc.2025 EndofYear Setup & Weekly High Potential Stock Alerts - mfd.ru
Can Astria Therapeutics Inc. ride the EV wave2025 Earnings Surprises & Technical Analysis for Trade Confirmation - mfd.ru
Is Astria Therapeutics Inc.’s ROE strong enoughTrade Volume Summary & Weekly Sector Rotation Insights - mfd.ru
BioCryst (BCRX) Poised for Growth with Key Acquisition and Positive Outlook - GuruFocus
Former 5% holder Vestal Point reports 0% stake in Astria (ATXS) - Stock Titan
Glazer Capital reveals 6.61% Astria Therapeutics (ATXS) stake in 13G/A - Stock Titan
Can Astria Therapeutics Inc. maintain its current growth rateJuly 2025 Trends & Capital Efficiency Focused Strategies - mfd.ru
Analyst Calls: Should I invest in Astria Therapeutics Inc before earnings2025 Year in Review & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Perceptive reports 0% stake in Astria Therapeutics (ATXS) after BioCryst deal - Stock Titan
BioCryst Acquisition Of Astria Highlights Rare Disease Focus And Valuation Gap - Yahoo Finance
All You Need to Know About Astria Therapeutics (ATXS) Rating Upgrade to Buy - MSN
Astria Therapeutics Inc Stock (ATXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):